Main Page | About | Editorial | Table of Contents | Archive | Search | Instructions to Authors | Contact
2016, Volume 7, Number 2, Page(s) 065-083
[ Summary ] [ PDF ] [ Mail to Author ] [ Mail to Editor ]
Intramedullary Spinal Cord Tumors: A Review and Discussion of Surgical Rationale
Jonathan G Hobbs3, Bhargav Desai1, Jacob S Young3, Sean P Polster3, Matthew K Tobin1, Joseph R Geraghty1, Andreas A Linninger2, Adetokunbo A. Oyelese4, John H. Shin5, Mohamad Bydon6, Ankit I Mehta1
1Department of Neurosurgery, University of Illinois at Chicago, Chicago, IL, USA
2Department of Bioengineering, University of Illinois at Chicago, Chicago, IL, USA
3Section of Neurosurgery, University of Chicago, Chicago IL, USA
4Department of Neurosurgery, Brown University, Providence RI, USA
5Department of Neurosurgery, Massachusetts General Hospital, Boston MA, USA
6Department of Neurosurgery, Mayo Clinic, Rochester MN, USA
Abstract
Intramedullary spinal cord tumors (IMSCTs) are rare neoplasms of the central nervous system associated with severe neurological deterioration, morbidity, poor quality of life, and even death. The most common IMSCTs that we encounter are ependymomas, astrocytomas, and hemangioblastomas. Surgery remains the initial treatment of choice for IMSCTs. New and interesting therapies are currently under investigation and the extent to which they augment our current treatment paradigms remains to be seen but with the advent of novel therapies (nanomedicine, localizable therapies, and cell targeting) the future appears promising for lesions not amenable to gross total resection and a surgical cure. While complete resection is not always achievable, we must remain tempered by the paramount importance of our patient's neurological function, for it is their wellbeing and quality of life outcome that is the root purpose of all of the aforementioned endeavors.
  • Top
  • Abstract
  • [ Top ] [ Summary ] [ PDF ] [ Mail to Author ] [ Mail to Editor ]